Telomir Pharmaceuticals is like an early-stage Gilead Sciences, but focused on developing novel oral drugs for age-related inflammatory conditions and cellular health.

• TELOMIR-1 (Drug Candidate): A novel oral small molecule in pre-clinical development designed as an in situ therapeutic treatment for human stem cells, functioning as a metal enzyme inhibitor to modulate pro-inflammatory cytokines and protect telomeres.
• TELOMIR-1 for Hemochromatosis Treatment: This application targets the reduction of iron overload by selectively binding iron, lowering blood iron levels, and disrupting IL-17 induced inflammatory pathways.
• TELOMIR-1 for Post-Chemotherapy Recovery: This intended use aims to serve as a complementary oral treatment to inhibit pro-inflammatory cytokines and reduce blood iron levels, potentially improving patient recovery and adherence to chemotherapy regimens.
• TELOMIR-1 for Osteoarthritis Treatment: TELOMIR-1 is also being investigated for its potential to treat age-related inflammatory conditions like osteoarthritis by modulating pro-inflammatory cytokines such as IL-17.

Telomir Pharmaceuticals (TELO) is a pre-clinical-stage pharmaceutical company. This means the company is currently focused on the research and development of its lead product candidate, TELOMIR-1, and has not yet advanced to clinical trials, regulatory approval, or commercialization.

As a pre-clinical-stage company, Telomir Pharmaceuticals does not currently have major customers for commercial products or services, as it is not yet selling any product to other companies or individuals.

Erez Aminov, Chairman and Chief Executive Officer

Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc.. He also holds the position of Chairman and Chief Executive Officer at MIRA Pharmaceuticals, Inc.. Mr. Aminov founded Locate Venture Corp., a consulting firm that supports early-stage biotech enterprises, and previously served as President of Finds4less Inc.. He played a key role in the initial public offerings of both MIRA Pharmaceuticals and Telomir Pharmaceuticals.

Alan Weichselbaum, CPA, MBA, Chief Financial Officer

Alan Weichselbaum serves as the Chief Financial Officer of Telomir Pharmaceuticals, Inc., a position he assumed effective May 15, 2025. He also holds the role of Chief Financial Officer for MIRA Pharmaceuticals, Inc.. Mr. Weichselbaum brings over 30 years of experience in corporate finance, capital markets, and strategic advisory. He founded The Wexus Group, an outsourced CFO advisory firm, and has been a Director of FinWise Bancorp (Nasdaq: FINW) since 2015. Earlier in his career, he held positions at Philip Morris Capital Corporation and began his professional journey at Price Waterhouse.

Itzchak Angel, PhD, Chief Scientific Advisor

Itzchak Angel is an accomplished executive with over 40 years of experience in the pharmaceutical industry, guiding medical, pharmaceutical, drug, and business development. Since 2005, he has served as President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.), where he provides assistance to pharmaceutical and biotechnology companies on various aspects of drug development.

Francis E. O'Donnell, Jr., MD, Senior Advisor

Dr. Francis E. O'Donnell, Jr. serves as a Senior Advisor, contributing to the company's strategy, direction, and execution of clinical development plans. He has thirty years of experience in pharmaceutical development and works with senior management to evaluate the scientific and clinical viability of potential products.

1. Clinical Development and Regulatory Approval Risk: Telomir Pharmaceuticals is a pre-clinical stage company, and its lead drug candidate, TELOMIR-1, has not yet been tested in humans. The success of TELOMIR-1 is entirely dependent on demonstrating safety and efficacy in future human clinical trials and subsequently obtaining regulatory approval from the FDA and comparable foreign regulators. Pre-clinical data, on which the company's current beliefs about TELOMIR-1 are based, "may prove inaccurate and is not necessarily indicative of future results." [Context] The drug development process has a high failure rate, with only about 3-5% of products graduating from initial pre-clinical testing to advanced clinical testing, and approximately 95% of drugs that show promise in pre-clinical testing failing Phase 1 clinical trials. While the company recently reported favorable IND-enabling GLP safety results for TELOMIR-1, supporting first-in-human clinical development, this does not eliminate the substantial risks inherent in clinical trials.
2. Competition from Established Treatments for Hemochromatosis: For hemochromatosis, one of Telomir's initial targeted indications, the primary current treatment is phlebotomy, which the company describes as "relatively inexpensive, well accepted, and well tolerated." [Context] Phlebotomy is the most commonly used and effective treatment for iron overload. Even if TELOMIR-1 receives approval, it would need to demonstrate significant advantages over this widely adopted standard of care to gain substantial market share, particularly for subgroups of patients where phlebotomy might be contraindicated or not fully effective [Context]. Existing iron chelators are also available, although they have limitations due to gastrointestinal and kidney toxicity [Context, 14].
3. Single Product Dependency: Telomir Pharmaceuticals' entire business and future prospects are predicated on the successful development and commercialization of TELOMIR-1. The company was organized specifically for the purpose of pursuing the development and commercialization of this single novel small molecule [Context]. Should TELOMIR-1 fail in clinical trials, encounter unexpected safety issues, or not receive regulatory approval for its targeted indications, the company's business, financial condition, and operational results would be severely and adversely impacted, as it has no other pipeline products mentioned at a comparable stage of development. Early-stage biotechs often rely on incremental funding, and the failure of their primary candidate can put the company's existence at risk.

Telomir Pharmaceuticals (TELO) is a pre-clinical-stage company focused on developing TELOMIR-1, an oral therapeutic treatment for human stem cells. Given its current stage, the primary drivers of future revenue growth over the next 2-3 years will stem from key advancements in the clinical development and regulatory pathways of its lead candidate, TELOMIR-1, for its targeted indications.

The expected drivers of future revenue growth for Telomir Pharmaceuticals include:

1. Successful Progression of TELOMIR-1 into and through Phase 1 Clinical Trials: As TELOMIR-1 is currently in the pre-clinical stage, initiating and successfully completing Phase 1 clinical trials to demonstrate safety and tolerability in humans will be a crucial step towards advancing the drug. This milestone is fundamental for all subsequent development and eventual commercialization, laying the groundwork for future revenue.
2. Advancement of TELOMIR-1 into Phase 2 Clinical Trials for Hemochromatosis: Telomir Pharmaceuticals has identified hemochromatosis as one of its initial targeted indications. Progressing TELOMIR-1 into Phase 2 trials for this condition would signify a significant step towards validating its efficacy, addressing an unmet medical need, and positioning it for potential future market entry and revenue generation in this area.
3. Advancement of TELOMIR-1 into Phase 2 Clinical Trials for Post-Chemotherapy Recovery: The company is also investigating TELOMIR-1 for post-chemotherapy recovery. Advancing the candidate into Phase 2 trials for this indication would further diversify its potential market, offering a complementary treatment to improve patient adherence and outcomes, thereby opening another significant avenue for future revenue.
4. Positive Data from Early-Stage Clinical Trials Demonstrating Safety and Preliminary Efficacy: Generating favorable data from Phase 1 and early Phase 2 clinical trials, particularly demonstrating both safety and initial signs of efficacy for TELOMIR-1 in its targeted indications (hemochromatosis and/or post-chemotherapy recovery), would significantly de-risk the asset. Such positive results are critical for attracting further investment, potential partnerships, and expediting the path towards regulatory approval and commercial success.

Share Issuance

• Telomir Pharmaceuticals completed its initial public offering (IPO) in February 2024, raising approximately $7 million in gross proceeds from the sale of 1,000,000 shares of common stock at $7.00 per share.
• In December 2024, the company issued 142,857 shares of common stock at a price of $7.00 per share, totaling $1 million, to an accredited investor.
• The company secured $3 million in equity financing in May 2025 through a direct investment from The Bayshore Trust, involving the purchase of 1 million restricted shares at $3.00 per share.

Inbound Investments

• An accredited investor (The Starwood Trust) provided a $5 million non-dilutive line of credit to the company earlier in 2024, which remained undrawn.
• In December 2024, The Starwood Trust, an affiliated entity of the company's largest shareholder, made a $1 million equity investment by purchasing common stock.
• As part of a binding Letter of Intent to acquire TELI Pharmaceuticals in October 2025, certain TELI shareholders committed up to $5 million in cash contributions, including $1 million at closing, $2 million upon FDA IND acceptance, and $2 million upon Phase 1/2 initiation.